Validating a Blood Test with a Prospective Cohort of 100,000 Participants
The STRIVE Study is a prospective, observational, longitudinal, cohort study that has enrolled approximately 100,000 women at the time of their screening mammogram. STRIVE will be used to validate a blood test for the early detection of multiple cancer types. Participants completed a health questionnaire and provided a blood sample around the time of their screening mammogram and will be followed for up to five years to capture clinical outcome data, including cancer diagnoses.
Current Status: Follow-up
Thank You for Your Contribution
GRAIL and it’s collaborators would like to extend a big thank you to all the participants across the United States who contributed to the STRIVE Study. Your participation in the STRIVE Study is bringing GRAIL and its collaborators one step closer to developing an important new tool to detect cancer early.
- Cleveland Clinic
- Henry Ford Health System
- Mayo Clinic
- Sarah Cannon
- Scottsdale Medical Imaging
- Sutter Health
Participants are women who had a screening mammogram at a participating medical center and provided written informed consent.